Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) is a charitable organization dedicated to multiple myeloma, an incurable blood cancer. The MMRF runs as if it were a for-profit business, expecting high returns from the money the organization raises from donors.[1]

History

MMRF was founded in 1998 by twin sisters Kathy Giusti and Karen Andrews, following Kathy's diagnosis with multiple myeloma. Giusti, a pharmaceutical company executive and Harvard Business School Alum, wanted to encourage researchers to develop treatments for multiple myeloma by using business models rather than academic models of drug development.[1]

About The MMRF

MMRF is a private funder of multiple myeloma research, having raised over $120 million since its inception to contribute funding to more than 120 laboratories worldwide.[2] MMRF funding contributes to diverse research strategies to yield long-, mid-, and short-term results in an effort to deliver better treatments to patients faster: basic science programs to better understand the disease and identify new druggable targets through genomics and proteomics research; validation programs to prioritize new compounds and combinations based on key targets; and clinical trials conducted at a number of myeloma centers.

In 2009, the MMRF funded research into 30 compounds at the pre-clinical stage.[3] By 2013 it had raised more than $250 million and its work has helped gain approval of six new drugs to treat the disease.[4]

See also

Notes
  1. Groopman, Jerome (January 28, 2008). "Buying a Cure.(Kathy Giusti's Multiple Myeloma Research Foundation)". The New Yorker. Retrieved 16 December 2009.
  2. "Harvard Business School Awards MMRF Founder, CEO with Alumni Achievement Award". Reuters (Business wire). 2009-10-22. Archived from the original on 2016-03-03. Retrieved 16 December 2009.
  3. Duxbury, Sarah (December 8, 2006). "Foundations move in where VCs fear to tread". San Francisco Business Times. Retrieved 16 December 2009.
  4. "A Mission with Precision", Forbes Magazine, December 3, 2013
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.